

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/712,360	11/13/2003	Miguel A. Guerra	59393US002	1425	
32692	7590 07/14/2006		EXAMINER		
3M INNOVATIVE PROPERTIES COMPANY PO BOX 33427			TRUONG, DUC		
ST. PAUL, MN 55133-3427		ART UNIT	PAPER NUMBER		
		1711			
			DATE MAILED: 07/14/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

1	·	•	

	Application No.	Applicant(s)				
	10/712,360	GUERRA ET AL.				
Office Action Summary	Examiner	Art Unit				
	Duc Truong	1711				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on						
2a) This action is FINAL . 2b) ⊠ This	action is non-final.	1				
3) Since this application is in condition for allowar	nce except for formal matters, pro	secution as to the merits is				
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	i3 O.G. 213.				
Disposition of Claims						
 4) ☐ Claim(s) 1-47 is/are pending in the application. 4a) Of the above claim(s) 8 and 18-47 is/are withdrawn from consideration. 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1-7 and 9-17 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or election requirement. 						
Application Papers						
9) The specification is objected to by the Examine	r.					
10) The drawing(s) filed on is/are: a) acce	epted or b) objected to by the E	Examiner.				
Applicant may not request that any objection to the	drawing(s) be held in abeyance. See	37 CFR 1.85(a).				
Replacement drawing sheet(s) including the correcti	ion is required if the drawing(s) is obj	ected to. See 37 CFR 1.121(d).				
11)☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment(s)	4) Interview Summary	(DTO 440)				
1)	Paper No(s)/Mail Da	ite				
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	5) Notice of Informal Page 1990. 6) Other:	atent Application (PTO-152)				

Application/Control Number: 10/712,360

Art Unit: 1711

DETAILED ACTION

Applicant's election of Group I, claims 1-7 and 9-17 and the bisamidine group in claim 11 and 17 as elected species in the reply filed on 4/24/06 is acknowledged.

Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-7 and 9-17 are rejected under 35 U.S.C. 103(a) as being unpatentable over EP 0422231 in view of EP 1238999, both of record on 1449.

EP 0422231 discloses a polytriazine produced from polyimidoylamidine (see page 2, lines 5-6) or the claimed bisamidine (see page 3, formula (4)) with a polymer comprising a fluorinated backbone and a pendent group, such as carbonyl halide (see page 4, line 12; page 18, lines 30-44; page 21, lines 1-35).

The disclosure of the reference differs from the instant claims in that it neither disclose the pendent sulfonyl fluoride group in claim 7 nor the bisamidine compound in claim 11 nor the converting step from sulfonyl halide to sulfonic acid group.

However, the reference does disclose the use of a bisamidine, as stated above in that Rfo can be considered C4H8 and the acyl fluoride, as stated above, having the same functionality with sulfonyl halide.

Application/Control Number: 10/712,360

Art Unit: 1711

EP 1238999 discloses the fluorinated polymers in that the acyl fluoride and sulfonyl fluoride have the sane functionality (see page 4, [0027], claims 7-9) and the step of converting the sulfonyl group into sulfonic acid group (see page 12, claim 20, step (b)). Therefore, it would have been obvious to one of ordinary skill in the art to select the sulfonyl halide from the reference to replace the acyl halide in the claims, based on functionality, and including the step of converting the sulfonyl halide group into the sulfonic acid group from the reference into the claims in order to gain the advantages of the combination of the references, that being hydrophilic membranes having the ionic conductivity and a water permeability.

The EP 0422231 discloses polytriazine produced from fluorinated acyl fluoride with bisamidine.

The EP 1238999 provides evidence that fluorinated acyl halide and fluorinated sulfonyl halide have the same functionality.

The replacement of said sulfonyl halide by acyl halide, as disclosed in EP 1238999, in the polytriazine of EP 0422231, to have the added properties, would not provide an unexpected result to one of ordinary skill in the art.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Duc Truong whose telephone number is 571-272-1081. The examiner can normally be reached on Monday-Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Seidleck can be reached on 571-272-1078. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/712,360 Page 4

Art Unit: 1711

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

DUCTRUONG PRIMARY EXAMINER